- 學位論文
大豆蛋白對非酒精性脂肪肝病患者之影響
The effects of soy protein on patients with non-alcoholic fatty liver disease
摘要
非酒精性脂肪肝在台灣盛行率約11.4% ~ 41%，是一重大的健康課題。本研究設計以單臂、開放性、為期十二週的臨床試驗，使用大豆蛋白介入非酒精性脂肪肝患者，比較介入後血中ALT改善狀況之臨床試驗。受試者被給予含大豆蛋白之補充劑，每日早餐食用一份，連續十二週，同時不改變飲食及生活習慣。評估項目包括：血液生化值、肝脂肪纖維化掃描以及腸道菌相。最終有28名受試者完成研究，研究結果發現大豆蛋白補充劑介入12週後ALT顯著下降，HDL-C及IGFBP-3顯著上升。大豆蛋白的補充能顯著降低其中25名非酒精性脂肪肝病患者的ALT，同時本研究也發現大豆蛋白可能改善與代謝症候群相關的臨床指標。
並列摘要
In Taiwan, the issue of NAFLD is important which’s prevalence is about 11.4% ~ 41%. This study is a single arm, open labeled, 12 weeks clinical trial to evaluate the effect of soy protein supplementation on ALT function. Supplements were consumed as a beverage once daily in breakfast. Participants were provided the treatment for 12 weeks and keep the original dietary behavior and lifestyle. The examination includes blood biochemical parameters, fibroscan and gut microflora. A total of 28 patients enrolled in this study. Each patient completed blood examination, physical examination, FibroScan test, and diet questionnaire before and after soy protein treatment. The comparisons of examination values between patients before and after soy protein treatment showed that there were significant difference on ALT, HDL- cholesterol and IGFBP-3. Soy protein supplementations significantly reduced the ALT level in 25 NAFLD patients. This study also showed that soy protein could improve the clinical characteristics related with metabolic syndrome.